Versant Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.08K Buy
2,108
+1,117
+113% +$6.53K ﹤0.01% 2294
2026
Q2
$7.94K Sell
991
-547
-36% -$4.7K ﹤0.01% 2303
2026
Q1
$12.4K Sell
1,538
-1,036
-40% -$9.9K ﹤0.01% 2046
2025
Q4
$30K Buy
2,574
+1,231
+92% +$12K ﹤0.01% 1387
2025
Q3
$13.5K Buy
1,343
+721
+116% +$10.3K ﹤0.01% 1796
2025
Q2
$10.9K Hold
622
– – ﹤0.01% 1855
2025
Q1
$7.82K Buy
+622
New +$7.48K ﹤0.01% 1842

Other funds holding SPRY

Versant Capital Management's SPRY Position: Q3 2026 in Review

Versant Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 113% in Q3 2026, buying an estimated $6.53K and bringing the position to 2,108 shares worth $9.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2294.

Versant Capital Management first reported a position in SPRY in Q1 2025 and has held it in 7 quarters since. The position peaked at $30K in Q4 2025. 191 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Versant Capital Management held 2,108 shares of ARS Pharmaceuticals worth $9.08K as of Q3 2026.
  • Versant Capital Management bought 1,117 ARS Pharmaceuticals shares in Q3 2026, an estimated $6.53K.
  • ARS Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2294 holding.
  • Versant Capital Management first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • Versant Capital Management's ARS Pharmaceuticals position peaked at $30K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.